Search Results Search Sort by RelevanceMost Recent Case and Commentary Jan 2020 How Should Public Health Officials Respond When Important Local Rituals Increase Risk of Contagion? Esther Mokuwa, MSc and Paul Richards, PhD, MA During one 2014 Ebola epidemic, arrival of “safe burial” teams was often delayed. Some buried their loved ones themselves, which undermined containment efforts. AMA J Ethics. 2020;22(1):E5-9. doi: 10.1001/amajethics.2020.5. Case and Commentary May 2022 How Should Clinicians Respond to Patient Interest in Dietary Supplements to Treat Serious Chronic Illness? Valerie Clinard, PharmD, APh and Jennifer D. Smith, PharmD, BCACP, BC-ADM, CDCES Consumption of over-the-counter vitamins, minerals, and herbals is widespread, but clinicians lack critical information about their use. AMA J Ethics. 2022;24(5):E361-367. doi: 10.1001/amajethics.2022.361. Case and Commentary May 2022 ¿Cómo deberían responder los médicos al interés de los pacientes sobre suplementos dietético para tratar enfermedades crónicas graves? Valerie Clinard, PharmD, APh and Jennifer D. Smith, PharmD, BCACP, BC-ADM, CDCES AMA J Ethics. 2022;E361-367. doi: 10.1001/amajethics.2022.361. Case and Commentary Aug 2005 Hoping for the Best, Preparing for the Worst: Physician to Patient in Clinical Trial Frederic W. Platt, MD Virtual Mentor. 2005;7(8):541-546. doi: 10.1001/virtualmentor.2005.7.8.ccas2-0508. Case and Commentary Nov 2004 Clinical Trials and End-of-Life Decision Making, Commentary 1 David S. Alberts, MD Virtual Mentor. 2004;6(11):477-479. doi: 10.1001/virtualmentor.2004.6.11.ccas1-0411. Case and Commentary Nov 2004 Clinical Trials and End-of-Life Decision Making, Commentary 2 Lucy Godley, MD, PhD Virtual Mentor. 2004;6(11):479-481. doi: 10.1001/virtualmentor.2004.6.11.ccas1-0411. Case and Commentary Nov 2004 Heads or Tails: Randomized Placebo-Controlled Trials, Commentary 1 Charles Weijer, MD, PhD Virtual Mentor. 2004;6(11):482-484. doi: 10.1001/virtualmentor.2004.6.11.ccas2-0411. Case and Commentary Nov 2004 Heads or Tails: Randomized Placebo-Controlled Trials, Commentary 2 Karen Kreiner, MD Virtual Mentor. 2004;6(11):484-485. doi: 10.1001/virtualmentor.2004.6.11.ccas2-0411. Case and Commentary Nov 2004 Who Is That? Expanding the Clinical Encounter Vijaya Arekapudi, MD Virtual Mentor. 2004;6(11):486-487. doi: 10.1001/virtualmentor.2004.6.11.ccas3-0411. Case and Commentary Nov 2005 Controlling Diabetes Robert P. Hoffman, MD Virtual Mentor. 2005;7(11):723-726. doi: 10.1001/virtualmentor.2005.7.11.ccas1-0511. Pagination Current page 1 Page 2 Page 3 Page 4 Next page Next › Last page Last »
Case and Commentary Jan 2020 How Should Public Health Officials Respond When Important Local Rituals Increase Risk of Contagion? Esther Mokuwa, MSc and Paul Richards, PhD, MA During one 2014 Ebola epidemic, arrival of “safe burial” teams was often delayed. Some buried their loved ones themselves, which undermined containment efforts. AMA J Ethics. 2020;22(1):E5-9. doi: 10.1001/amajethics.2020.5.
Case and Commentary May 2022 How Should Clinicians Respond to Patient Interest in Dietary Supplements to Treat Serious Chronic Illness? Valerie Clinard, PharmD, APh and Jennifer D. Smith, PharmD, BCACP, BC-ADM, CDCES Consumption of over-the-counter vitamins, minerals, and herbals is widespread, but clinicians lack critical information about their use. AMA J Ethics. 2022;24(5):E361-367. doi: 10.1001/amajethics.2022.361.
Case and Commentary May 2022 ¿Cómo deberían responder los médicos al interés de los pacientes sobre suplementos dietético para tratar enfermedades crónicas graves? Valerie Clinard, PharmD, APh and Jennifer D. Smith, PharmD, BCACP, BC-ADM, CDCES AMA J Ethics. 2022;E361-367. doi: 10.1001/amajethics.2022.361.
Case and Commentary Aug 2005 Hoping for the Best, Preparing for the Worst: Physician to Patient in Clinical Trial Frederic W. Platt, MD Virtual Mentor. 2005;7(8):541-546. doi: 10.1001/virtualmentor.2005.7.8.ccas2-0508.
Case and Commentary Nov 2004 Clinical Trials and End-of-Life Decision Making, Commentary 1 David S. Alberts, MD Virtual Mentor. 2004;6(11):477-479. doi: 10.1001/virtualmentor.2004.6.11.ccas1-0411.
Case and Commentary Nov 2004 Clinical Trials and End-of-Life Decision Making, Commentary 2 Lucy Godley, MD, PhD Virtual Mentor. 2004;6(11):479-481. doi: 10.1001/virtualmentor.2004.6.11.ccas1-0411.
Case and Commentary Nov 2004 Heads or Tails: Randomized Placebo-Controlled Trials, Commentary 1 Charles Weijer, MD, PhD Virtual Mentor. 2004;6(11):482-484. doi: 10.1001/virtualmentor.2004.6.11.ccas2-0411.
Case and Commentary Nov 2004 Heads or Tails: Randomized Placebo-Controlled Trials, Commentary 2 Karen Kreiner, MD Virtual Mentor. 2004;6(11):484-485. doi: 10.1001/virtualmentor.2004.6.11.ccas2-0411.
Case and Commentary Nov 2004 Who Is That? Expanding the Clinical Encounter Vijaya Arekapudi, MD Virtual Mentor. 2004;6(11):486-487. doi: 10.1001/virtualmentor.2004.6.11.ccas3-0411.
Case and Commentary Nov 2005 Controlling Diabetes Robert P. Hoffman, MD Virtual Mentor. 2005;7(11):723-726. doi: 10.1001/virtualmentor.2005.7.11.ccas1-0511.